The new year is only a few days old but M&A activity is already underway in Europe with Italy’s Angelini Pharma agreeing to acquire Swiss CNS specialist Arvelle Therapeutics GmbH in a deal worth up to $960m.
The Rome-headquartered company, which is part of the privately owned Angelini Holding founded in 1919, said it was creating "a leading European innovator in central nervous system and mental health disorder treatments" by buying Arvelle and its anti-epileptic drug cenobamate, which is currently under review in Europe. Arvelle raised $207
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?